Clinical Trial Update: Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD) [Phase 3]

View source ↗

Summary

A Phase 3 trial of the investigative agent RPH-104 for Adult-Onset Still's Disease has been withdrawn, and will not proceed as planned.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adult-onset Still Disease

Drugs mentioned

• RPH-104

Snippet

Sponsor: R-Pharm International, LLC | Conditions: Adult-Onset Still's Disease, AOSD | Phase 3 | Status: WITHDRAWN